Research programme: glucose metabolism disorder therapeutics - AdociaAlternative Names: BioChaperone glargine dulaglutide; BioChaperone glargine liraglutide; BioChaperone glucagon
Latest Information Update: 29 Sep 2016
At a glance
- Originator Adocia
- Class Antihypoglycaemics; Pancreatic hormones
- Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide 1 modulators; Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetes mellitus; Hypoglycaemia